Distinguished Professor
UC Davis Health
Sacramento, California
Randi Hagerman MD is a Developmental and Behavioral Pediatrician at the UC Davis MIND Institute. Dr. Hagerman has worked in the fragile X field for 40 years. She and her husband Dr. Paul Hagerman discovered FXTAS in 1998 and published the first cases in 2001. Since, she has seen over 250 cases of FXTAS and has received 24 years of NIH funding to study premutation carriers, which has included her detailed characterization of the FXTAS phenotype. Dr. Hagerman has also carried out multiple treatment studies in FXTAS, which have included a randomized controlled trial (RCT) of memantine and an open label study of sulforaphane and IV treatment with allopregnanolone. We are currently working with PureTech, a company that developed an oral allopregnanolone treatment and the DOD is funding a clinical trial of this medication for individuals with FXTAS. Dr Hagerman has also carried out numerous RCTs in both children and adults with Fragile X syndrome.
Disclosure information not submitted.